Skip to main content
. 2017 Aug 4;8(40):68208–68220. doi: 10.18632/oncotarget.19919

Figure 2. Sorafenib inhibits BV6-induced phosphorylation of MLKL in AML cells.

Figure 2

(A) Molm13 and MV4-11 cells were treated for 4½ hours (Molm13) or 11 hours (MV4-11) with 3 μM BV6 and 40 μM zVAD.fmk in the presence or absence of 10 μM Sorafenib, 15 μM GSK’872 or 5 μM Dabrafenib. (B) Molm13 and MV4-11 cells were treated for 5½ hours (Molm13) or 7 hours (MV4-11) with 3 μM BV6 and 40 μM zVAD.fmk in the presence or absence of 10 μM Sorafenib, 15 μM GSK’872 or 5 μM Dabrafenib. Expression levels of MLKL and phospho-MLKL (A) or cIAP1 (B) were assessed by Western blotting, GAPDH served as loading control.